Richter acquires Celmatix research portfolio

The assets acquired from Celmatix include a unique, oral follicle-stimulating hormone (FSH) receptor agonist that could transform infertility care by enabling more favorable ovarian stimulation for patients, they wrote.

The portfolio also includes a novel Jun N-terminal kinase (JNK) inhibitor, which offers a potential, non-hormonal immunotherapy approach for the treatment of endometriosis, with positive effects on both pain and inflammation.

In addition, the deal includes early-stage therapeutic antibodies targeting anti-Müllerian hormone (AMH), including both agonists and antagonists, which may provide unprecedented control over ovarian folliculogenesis.

The transaction is consistent with Richter’s strategy to expand its innovative drug development capabilities in key gynecological indications, including infertility treatment, endometriosis and ovarian aging.

Development of the acquired programs will be led by Richter’s gynecological research and development center in Belgium, Richter said.

It added that under the asset purchase agreement, Celmatix will receive an upfront payment and will be eligible for additional milestone payments as the drug development progresses into the clinical and registration phases.

Richter Gedeon Plc. achieved consolidated sales of HUF 928.96 billion in 2025, which is 8.3 percent higher than a year earlier, while its after-tax profit decreased by 3 percent to HUF 232.22 billion. The pharmaceutical company’s shares are listed in the premium category of the BSE. The paper closed Monday’s trading at HUF 11,840, and its price has fluctuated between HUF 9,380 and HUF 12,250 over the past year.